Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS

The aim of this study is to establish and validate a rapid, selective, and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to determine tubeimoside I (TBMS-I) in ICR (Institute of Cancer Research) mouse whole blood and its application in the pharmacokin...

Full description

Saved in:
Bibliographic Details
Main Authors: Lianguo Chen, Qinghua Weng, Feifei Li, Jinlai Liu, Xueliang Zhang, Yunfang Zhou
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Analytical Methods in Chemistry
Online Access:http://dx.doi.org/10.1155/2018/9074893
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832564164246110208
author Lianguo Chen
Qinghua Weng
Feifei Li
Jinlai Liu
Xueliang Zhang
Yunfang Zhou
author_facet Lianguo Chen
Qinghua Weng
Feifei Li
Jinlai Liu
Xueliang Zhang
Yunfang Zhou
author_sort Lianguo Chen
collection DOAJ
description The aim of this study is to establish and validate a rapid, selective, and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to determine tubeimoside I (TBMS-I) in ICR (Institute of Cancer Research) mouse whole blood and its application in the pharmacokinetics and bioavailability study. The blood samples were precipitated by acetonitrile to extract the analytes. Chromatographic separation was performed on a UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm). The mobile phase consisted of water with 0.1% formic acid and methanol (1 : 1, v/v) at a flow rate of 0.4 mL/min. The total eluting time was 4 min. The TBMS-I and ardisiacrispin A (internal standard (IS)) were quantitatively detected by a tandem mass spectrometry equipped with an electrospray ionization (ESI) in a positive mode by multiple reaction monitoring (MRM). A validation of this method was in accordance with the US Food and Drug Administration (FDA) guidelines. The lower limit of quantification (LLOQ) of TBMS-I was 2 ng/mL, and the calibration curve was linearly ranged from 2 to 2000 ng/mL (r2 ≥ 0.995). The relative standard deviation (RSD) of interday precision and intraday precision was both lower than 15%, and the accuracy was between 91.7% and 108.0%. The average recovery was >66.9%, and the matrix effects were from 104.8% to 111.0%. In this assay, a fast, highly sensitive, and reproducible quantitative method was developed and validated in mouse blood for the first time. The absolute availability of TBMS-I in the mouse was only 1%, exhibiting a poor oral absorption.
format Article
id doaj-art-f897af4c4d0f44adbac44b371fe2085c
institution Kabale University
issn 2090-8865
2090-8873
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Journal of Analytical Methods in Chemistry
spelling doaj-art-f897af4c4d0f44adbac44b371fe2085c2025-02-03T01:11:42ZengWileyJournal of Analytical Methods in Chemistry2090-88652090-88732018-01-01201810.1155/2018/90748939074893Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MSLianguo Chen0Qinghua Weng1Feifei Li2Jinlai Liu3Xueliang Zhang4Yunfang Zhou5Wenzhou People’s Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou 325000, ChinaWenzhou People’s Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou 325000, ChinaWenzhou People’s Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou 325000, ChinaWenzhou People’s Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou 325000, ChinaWenzhou People’s Hospital, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou 325000, ChinaLaboratory of Clinical Pharmacy, The People’s Hospital of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, ChinaThe aim of this study is to establish and validate a rapid, selective, and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to determine tubeimoside I (TBMS-I) in ICR (Institute of Cancer Research) mouse whole blood and its application in the pharmacokinetics and bioavailability study. The blood samples were precipitated by acetonitrile to extract the analytes. Chromatographic separation was performed on a UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm). The mobile phase consisted of water with 0.1% formic acid and methanol (1 : 1, v/v) at a flow rate of 0.4 mL/min. The total eluting time was 4 min. The TBMS-I and ardisiacrispin A (internal standard (IS)) were quantitatively detected by a tandem mass spectrometry equipped with an electrospray ionization (ESI) in a positive mode by multiple reaction monitoring (MRM). A validation of this method was in accordance with the US Food and Drug Administration (FDA) guidelines. The lower limit of quantification (LLOQ) of TBMS-I was 2 ng/mL, and the calibration curve was linearly ranged from 2 to 2000 ng/mL (r2 ≥ 0.995). The relative standard deviation (RSD) of interday precision and intraday precision was both lower than 15%, and the accuracy was between 91.7% and 108.0%. The average recovery was >66.9%, and the matrix effects were from 104.8% to 111.0%. In this assay, a fast, highly sensitive, and reproducible quantitative method was developed and validated in mouse blood for the first time. The absolute availability of TBMS-I in the mouse was only 1%, exhibiting a poor oral absorption.http://dx.doi.org/10.1155/2018/9074893
spellingShingle Lianguo Chen
Qinghua Weng
Feifei Li
Jinlai Liu
Xueliang Zhang
Yunfang Zhou
Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
Journal of Analytical Methods in Chemistry
title Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
title_full Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
title_fullStr Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
title_full_unstemmed Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
title_short Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
title_sort pharmacokinetics and bioavailability study of tubeimoside i in icr mice by uplc ms ms
url http://dx.doi.org/10.1155/2018/9074893
work_keys_str_mv AT lianguochen pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms
AT qinghuaweng pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms
AT feifeili pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms
AT jinlailiu pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms
AT xueliangzhang pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms
AT yunfangzhou pharmacokineticsandbioavailabilitystudyoftubeimosideiinicrmicebyuplcmsms